Clinic
Saratoga Hospital
Saratoga Hospital was paid $40.10M by Medicaid between Jan 2018 and Dec 2024, across 392 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 22% of everything it billed.
33Billing provider infoSARATOGA HOSPITAL
SARATOGA SPRINGS, NY 12866
SARATOGA SPRINGS, NY 12866
33aNPI1073569331assigned 05/26/2006
33bProvider typeEmergency Care Clinic/Center
28Total paid$40.10M
24GClaims878,508
24DCodes billed392
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in New York
Rank by total paid#2 of 8
Median peer was paid$180K
This provider vs. median223×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,859 | $274K | |
| 2019 | 57,451 | $2.48M | |
| 2020 | 130,364 | $5.92M | |
| 2021 | 193,098 | $8.47M | |
| 2022 | 180,805 | $8.14M | |
| 2023 | 181,629 | $8.47M | |
| 2024incomplete | 130,302 | $6.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 22% | 80,379 | 68,337 | $8.86M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.3% | 36,815 | 35,591 | $3.32M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.5% | 25,840 | 24,788 | $2.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.9% | 19,047 | 17,823 | $1.98M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.1% | 25,713 | 22,733 | $1.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.0% | 14,790 | 14,106 | $1.62M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.8% | 18,539 | 5,470 | $1.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 10,954 | 10,382 | $1.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 4,253 | 4,158 | $1.16M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.8% | 5,534 | 4,536 | $1.12M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 3,953 | 3,805 | $1.03M |
| 80053 | Comprehensive metabolic panel | 1.8% | 36,751 | 32,519 | $736K |
380 more codes
| 99203 | Doctor's office visit, new patient (routine) | 1.5% | 5,701 | $614K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 4,568 | $566K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 6,604 | $545K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 786 | $455K |
| 93975 | 1.1% | 1,238 | $454K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 3,847 | $369K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,258 | $361K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,258 | $347K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12,106 | $310K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 17,146 | $306K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,407 | $303K |
| 97163 | <1% | 2,108 | $284K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,526 | $273K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 1,132 | $259K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,412 | $256K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,160 | $255K |
| G0378 | Hospital observation service, per hour | <1% | 761 | $242K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,104 | $241K |
| 59025 | Fetal non-stress test | <1% | 1,366 | $240K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,719 | $216K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24,120 | $198K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,588 | $179K |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,680 | $170K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,298 | $167K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,466 | $167K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 284 | $161K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,867 | $160K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,268 | $130K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 328 | $129K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,304 | $129K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,171 | $123K |
| 51798 | <1% | 404 | $122K | |
| 12001 | <1% | 284 | $108K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 90 | $107K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 823 | $105K |
| 90837 | Psychotherapy session, about an hour | <1% | 800 | $103K |
| 99050 | <1% | 8,102 | $89K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,956 | $89K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,213 | $87K |
| 36416 | <1% | 4,407 | $87K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 884 | $84K |
| 99218 | <1% | 167 | $83K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,334 | $83K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 794 | $82K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 343 | $79K |
| 92060 | <1% | 1,249 | $79K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,292 | $77K |
| 76000 | <1% | 409 | $75K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 277 | $73K |
| 90686 | <1% | 2,726 | $71K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 10,404 | $69K |
| 76830 | Ultrasound, transvaginal | <1% | 1,966 | $69K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,341 | $66K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 660 | $66K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 807 | $59K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 477 | $57K |
| 92567 | <1% | 832 | $57K | |
| 90715 | <1% | 1,989 | $55K | |
| 86850 | <1% | 2,379 | $54K | |
| 88142 | <1% | 2,527 | $53K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,300 | $53K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,830 | $50K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,702 | $50K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,213 | $47K |
| 80061 | Lipid panel | <1% | 6,405 | $46K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 445 | $45K |
| 97161 | <1% | 525 | $45K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 132 | $45K |
| 93971 | <1% | 830 | $43K | |
| 70496 | <1% | 188 | $43K | |
| 64615 | <1% | 125 | $43K | |
| 82728 | <1% | 3,492 | $42K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 532 | $42K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,277 | $41K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 113 | $40K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,408 | $40K |
| 92557 | <1% | 677 | $38K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,524 | $37K |
| 86901 | <1% | 2,470 | $37K | |
| 76801 | <1% | 672 | $37K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,227 | $37K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 25 | $36K |
| 71271 | <1% | 867 | $33K | |
| 86900 | <1% | 2,469 | $32K | |
| 88342 | <1% | 817 | $31K | |
| 93017 | <1% | 259 | $30K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 858 | $29K |
| 99152 | <1% | 2,772 | $29K | |
| 71250 | <1% | 275 | $29K | |
| 62323 | <1% | 70 | $28K | |
| 84439 | <1% | 3,913 | $27K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 160 | $25K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 475 | $25K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,895 | $25K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 43 | $24K |
| 88304 | <1% | 942 | $23K | |
| 81025 | <1% | 6,946 | $22K | |
| 76642 | <1% | 953 | $22K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,190 | $21K |
| 83880 | <1% | 812 | $21K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,467 | $21K |
| 94010 | <1% | 870 | $21K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,070 | $20K |
| 92133 | <1% | 249 | $20K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 679 | $20K |
| 96160 | <1% | 379 | $19K | |
| 82607 | <1% | 1,713 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,615 | $17K |
| 93970 | <1% | 43 | $17K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 898 | $17K |
| 12011 | <1% | 41 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,486 | $16K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 307 | $16K |
| 11721 | <1% | 382 | $16K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 344 | $16K |
| 76536 | <1% | 534 | $15K | |
| H0001 | Alcohol and/or drug assessment | <1% | 115 | $15K |
| 92250 | <1% | 210 | $15K | |
| 80362 | <1% | 1,585 | $15K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,205 | $14K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 88 | $14K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 550 | $14K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,581 | $13K |
| 99051 | <1% | 1,315 | $13K | |
| 99205 | Prolong outpt/office vis | <1% | 110 | $13K |
| 97165 | <1% | 229 | $12K | |
| 84153 | <1% | 773 | $12K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 882 | $12K |
| 70486 | <1% | 309 | $12K | |
| 76775 | <1% | 269 | $12K | |
| 90750 | <1% | 83 | $12K | |
| 76641 | <1% | 390 | $11K | |
| 99493 | <1% | 322 | $11K | |
| 85027 | <1% | 3,830 | $11K | |
| 64493 | <1% | 111 | $11K | |
| 86803 | <1% | 1,307 | $11K | |
| D2394 | <1% | 117 | $11K | |
| 84702 | <1% | 1,786 | $10K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 96 | $10K |
| 58300 | <1% | 96 | $10K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 137 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,455 | $8K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 13 | $8K |
| 64635 | <1% | 16 | $8K | |
| 97803 | <1% | 334 | $8K | |
| 76770 | <1% | 40 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 215 | $8K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 75 | $8K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 80 | $7K |
| 83540 | <1% | 1,784 | $7K | |
| 86618 | <1% | 1,014 | $7K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 17 | $7K |
| 83735 | <1% | 9,415 | $7K | |
| 87468 | <1% | 222 | $7K | |
| 80305 | <1% | 5,335 | $7K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 15 | $7K |
| 83655 | <1% | 532 | $7K | |
| 83550 | <1% | 1,698 | $7K | |
| 87631 | <1% | 129 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,295 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,127 | $6K |
| 96367 | <1% | 88 | $6K | |
| 70491 | <1% | 24 | $6K | |
| 88307 | <1% | 64 | $5K | |
| 82570 | <1% | 1,165 | $5K | |
| 86140 | <1% | 2,047 | $5K | |
| 81003 | <1% | 11,433 | $5K | |
| 82043 | <1% | 1,093 | $5K | |
| 12002 | <1% | 12 | $4K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 97 | $4K |
| 97010 | <1% | 221 | $4K | |
| 76882 | <1% | 98 | $4K | |
| 85610 | <1% | 1,840 | $4K | |
| 87484 | <1% | 222 | $4K | |
| 81001 | <1% | 8,370 | $4K | |
| 72141 | <1% | 12 | $4K | |
| 70498 | <1% | 142 | $4K | |
| 80323 | <1% | 1,514 | $4K | |
| 87340 | <1% | 627 | $4K | |
| 87077 | <1% | 1,581 | $4K | |
| 31231 | <1% | 30 | $3K | |
| 86592 | <1% | 1,410 | $3K | |
| 86769 | <1% | 92 | $3K | |
| 90677 | <1% | 68 | $3K | |
| 74018 | <1% | 883 | $3K | |
| 97802 | <1% | 146 | $3K | |
| 64483 | <1% | 16 | $3K | |
| 87088 | <1% | 3,561 | $3K | |
| 72110 | <1% | 524 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,381 | $3K |
| 77066 | Tomosynthesis, mammo | <1% | 38 | $3K |
| 73630 | <1% | 2,299 | $3K | |
| 87081 | <1% | 669 | $3K | |
| 80299 | <1% | 3,691 | $3K | |
| 87469 | <1% | 153 | $3K | |
| 86747 | <1% | 177 | $3K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 29 | $3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 15 | $2K |
| 85652 | <1% | 1,977 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,392 | $2K |
| 73030 | <1% | 840 | $2K | |
| 99406 | <1% | 394 | $2K | |
| 80348 | <1% | 1,648 | $2K | |
| 84100 | <1% | 1,030 | $2K | |
| 83690 | <1% | 6,078 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 25 | $2K |
| 85730 | <1% | 729 | $2K | |
| 87186 | <1% | 1,208 | $2K | |
| 99407 | <1% | 49 | $2K | |
| 82784 | <1% | 157 | $2K | |
| J3490 | Unclassified drugs | <1% | 62 | $2K |
| 76857 | <1% | 144 | $2K | |
| 91322 | <1% | 18 | $2K | |
| 77080 | <1% | 28 | $2K | |
| 84484 | <1% | 7,131 | $2K | |
| 73130 | <1% | 950 | $2K | |
| 92015 | Determination of refractive state | <1% | 419 | $2K |
| 95806 | <1% | 556 | $2K | |
| 72100 | <1% | 166 | $2K | |
| 82962 | <1% | 2,990 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,292 | $2K |
| 86762 | <1% | 215 | $1K | |
| 82105 | <1% | 235 | $1K | |
| 80076 | <1% | 147 | $1K | |
| 73564 | <1% | 765 | $1K | |
| 73610 | <1% | 1,295 | $1K | |
| 99385 | <1% | 12 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 44 | $1K |
| 82746 | <1% | 121 | $1K | |
| 73110 | <1% | 537 | $1K | |
| 94729 | <1% | 92 | $1K | |
| 94727 | <1% | 115 | $1K | |
| 87625 | <1% | 40 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,042 | $999.78 |
| 74246 | <1% | 17 | $987.78 | |
| 90734 | <1% | 49 | $918.52 | |
| 82950 | <1% | 177 | $846.34 | |
| 87070 | <1% | 435 | $823.13 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 65 | $820.41 |
| 84403 | <1% | 36 | $818.27 | |
| 87205 | <1% | 826 | $799.48 | |
| 87641 | <1% | 38 | $798.77 | |
| 85379 | <1% | 1,165 | $777.46 | |
| 70310 | <1% | 930 | $771.70 | |
| 73502 | <1% | 269 | $769.97 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,061 | $739.93 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 858 | $739.53 |
| 76818 | <1% | 27 | $738.15 | |
| 82947 | <1% | 1,926 | $730.86 | |
| T2022 | Case management, per month | <1% | 13 | $719.72 |
| 80349 | <1% | 501 | $687.71 | |
| 85007 | <1% | 463 | $685.78 | |
| 90656 | <1% | 54 | $675.86 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 34 | $640.00 |
| 84480 | <1% | 242 | $637.61 | |
| 97035 | <1% | 36 | $623.15 | |
| 90480 | <1% | 18 | $584.05 | |
| 84703 | <1% | 2,614 | $582.13 | |
| 87040 | <1% | 1,645 | $550.51 | |
| 84146 | <1% | 28 | $536.83 | |
| 87210 | <1% | 281 | $503.65 | |
| 84436 | <1% | 159 | $476.64 | |
| 90732 | <1% | 12 | $475.75 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 412 | $462.46 |
| 86308 | <1% | 603 | $459.15 | |
| 82550 | <1% | 279 | $417.99 | |
| 82803 | <1% | 12 | $406.68 | |
| 86039 | <1% | 79 | $385.08 | |
| 76870 | <1% | 40 | $355.44 | |
| G0008 | Administration of influenza virus vaccine | <1% | 37 | $334.00 |
| 84156 | <1% | 120 | $329.33 | |
| 72040 | <1% | 55 | $321.63 | |
| 85014 | <1% | 144 | $320.92 | |
| 86787 | <1% | 39 | $318.75 | |
| 80320 | <1% | 4,916 | $312.09 | |
| 82747 | <1% | 40 | $307.20 | |
| 86038 | <1% | 57 | $288.82 | |
| 11719 | <1% | 27 | $285.39 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 302 | $280.80 |
| 86704 | <1% | 52 | $276.27 | |
| 82150 | <1% | 73 | $271.42 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 491 | $266.33 |
| 94060 | <1% | 13 | $261.60 | |
| 80324 | <1% | 145 | $250.00 | |
| 84550 | <1% | 73 | $241.63 | |
| 80346 | <1% | 228 | $235.00 | |
| 73140 | <1% | 294 | $227.11 | |
| 83605 | <1% | 902 | $213.95 | |
| 84481 | <1% | 25 | $207.99 | |
| 86706 | <1% | 38 | $191.90 | |
| 84425 | <1% | 24 | $186.79 | |
| 96376 | <1% | 1,832 | $172.34 | |
| 73620 | <1% | 163 | $168.93 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 17 | $149.59 |
| 90662 | <1% | 12 | $144.85 | |
| 86430 | <1% | 27 | $122.00 | |
| 90461 | <1% | 103 | $120.24 | |
| 73080 | <1% | 70 | $115.92 | |
| 73562 | <1% | 25 | $102.27 | |
| 72050 | <1% | 18 | $100.24 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 30 | $99.84 |
| 80321 | <1% | 172 | $96.86 | |
| 87807 | <1% | 83 | $94.32 | |
| 94760 | <1% | 3,621 | $90.79 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,869 | $82.44 |
| 86708 | <1% | 24 | $80.00 | |
| 71101 | <1% | 27 | $66.50 | |
| 82565 | <1% | 14 | $65.39 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 237 | $63.84 |
| 86580 | <1% | 12 | $60.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,087 | $58.09 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,782 | $51.15 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,651 | $48.35 |
| 87420 | <1% | 28 | $47.24 | |
| 83615 | <1% | 41 | $43.58 | |
| 81015 | <1% | 40 | $34.45 | |
| 74019 | <1% | 12 | $30.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 311 | $27.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,896 | $26.74 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 73 | $26.46 |
| 73590 | <1% | 25 | $25.45 | |
| 73090 | <1% | 29 | $25.32 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,460 | $25.18 |
| 87400 | <1% | 342 | $22.91 | |
| 83930 | <1% | 378 | $20.64 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,625 | $18.06 |
| 86617 | <1% | 12 | $15.49 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,723 | $15.45 |
| 82553 | <1% | 28 | $12.12 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 31 | $11.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 951 | $8.41 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 132 | $7.38 |
| 87071 | <1% | 246 | $6.92 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 187 | $3.75 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 97 | $2.09 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 278 | $1.58 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 188 | $0.98 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,440 | $0.89 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 930 | $0.35 |
| J1815 | Injection, insulin, per 5 units | 0% | 23 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 285 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 159 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 366 | $0.00 |
| 99496 | 0% | 43 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 40 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 14 | $0.00 |
| 3075F | 0% | 25 | $0.00 | |
| 99492 | 0% | 12 | $0.00 | |
| 96127 | 0% | 67 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 29 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 40 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 20 | $0.00 |
| 99494 | 0% | 50 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 40 | $0.00 |
| 64494 | 0% | 24 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 99 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 15 | $0.00 |
| 1036F | 0% | 38 | $0.00 | |
| C1769 | Guide wire | 0% | 25 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 76 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 150 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 166 | $0.00 |
| 3085F | 0% | 702 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 144 | $0.00 |
| 1159F | 0% | 343 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 127 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 40 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 16 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 101 | $0.00 |
| 69209 | 0% | 15 | $0.00 | |
| 1124F | 0% | 12 | $0.00 | |
| 81002 | 0% | 24 | $0.00 | |
| 64636 | 0% | 15 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 26 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 25 | $0.00 |
| 84145 | 0% | 14 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 69 | $0.00 |
| 3078F | 0% | 25 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 33 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTAHURA, KATHLEEN (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Saratoga Hospital | Saratoga Spgs, NY | $904K |
| Saratoga Hospital | Saratoga Springs, NY | $274K |
| Saratoga Hospital | Saratoga Springs, NY | $199K |
| Saratoga Hospital | Gansevoort, NY | $131K |
| Saratoga Hospital | Saratoga Springs, NY | $29K |
| Saratoga Hospital | Ballston Lake, NY | $13K |
| Saratoga Hospital | Saratoga Springs, NY | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.